Medicinova Inc. MNOV
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Medicinova Inc. (MNOV) is a healthcare company listed in the US with a market value of about $71M. In the twelve months to September 30, 2026 it had revenue of $935717 and net income of -$11M, a net margin of -1127.0%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -16%.
About Medicinova
Medicinova is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $4M in 2021 to $409657 in 2025, a decline of about 43.6% a year. It was profitable in 0 of the last 10 years in our data. It spends 1636% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $935717 | $409657 | — | $1M | — | $4M | — | — | — | — | — |
| Net income | -$11M | -$12M | -$11M | -$9M | -$14M | -$10M | -$14M | -$13M | -$15M | -$11M | -$11M |
| Free cash flow | -$10M | -$10M | -$11M | -$7M | -$13M | -$9M | -$11M | -$9M | -$9M | — | -$7M |
| EPS (diluted) | $-0.21 | $-0.24 | $-0.23 | $-0.17 | $-0.29 | $-0.21 | $-0.31 | $-0.30 | $-0.36 | $-0.32 | $-0.33 |
| Net margin | -1127.0% | -2928.8% | — | -857.2% | — | -251.0% | — | — | — | — | — |
| ROIC | — | -25.1% | -18.9% | -12.4% | -16.3% | -9.6% | -19.8% | -14.7% | -16.8% | -29.2% | -24.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $8.25, 491% above the current price; targets range from $6.00 to $11.00; the consensus rating is “none”; expected EPS is $-0.26 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Medicinova pay a dividend?
Not currently.
Is Medicinova a good stock to buy?
We do not give buy or sell advice. Medicinova scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.